Cantor Fitzgerald Issues Positive Estimate for AQST Earnings

Key Points

• Cantor Fitzgerald increased its FY2025 earnings estimate for Aquestive Therapeutics from ($0.67) to ($0.64) per share, while also predicting FY2026 earnings at ($0.75) EPS.
• The stock currently holds a consensus rating of "Buy" from seven analysts, with an average price target of $10.14.
• Aquestive Therapeutics reported earnings of ($0.14) per share for the recent quarter, surpassing analysts' estimates of ($0.18).

Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) - Stock analysts at Cantor Fitzgerald raised their FY2025 earnings estimates for shares of Aquestive Therapeutics in a note issued to investors on Wednesday, August 13th. Cantor Fitzgerald analyst K. Kluska now anticipates that the company will post earnings per share of ($0.64) for the year, up from their previous forecast of ($0.67). The consensus estimate for Aquestive Therapeutics' current full-year earnings is ($0.46) per share. Cantor Fitzgerald also issued estimates for Aquestive Therapeutics' FY2026 earnings at ($0.75) EPS.

Other research analysts have also issued reports about the stock. Oppenheimer assumed coverage on shares of Aquestive Therapeutics in a report on Monday, June 2nd. They issued an "outperform" rating and a $7.00 price target for the company. Zacks Research upgraded shares of Aquestive Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Wednesday, August 13th. Finally, HC Wainwright reiterated a "buy" rating and issued a $10.00 price objective on shares of Aquestive Therapeutics in a research report on Tuesday, June 17th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $10.14.

Aquestive Therapeutics Trading Down 2.3%

Shares of AQST traded down $0.10 during mid-day trading on Friday, reaching $4.09. The company had a trading volume of 148,640 shares, compared to its average volume of 1,509,657. The firm has a fifty day simple moving average of $3.78 and a 200-day simple moving average of $3.16. Aquestive Therapeutics has a fifty-two week low of $2.12 and a fifty-two week high of $5.80. The stock has a market cap of $407.37 million, a price-to-earnings ratio of -5.86 and a beta of 1.99.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last announced its quarterly earnings results on Monday, August 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.04. The business had revenue of $10.00 million during the quarter, compared to analysts' expectations of $11.32 million.

Institutional Investors Weigh In On Aquestive Therapeutics

Several large investors have recently made changes to their positions in AQST. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Aquestive Therapeutics by 6.0% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 47,098 shares of the company's stock worth $156,000 after buying an additional 2,649 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in Aquestive Therapeutics by 16.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 27,669 shares of the company's stock valued at $99,000 after purchasing an additional 3,821 shares during the period. MetLife Investment Management LLC lifted its position in Aquestive Therapeutics by 11.4% during the 4th quarter. MetLife Investment Management LLC now owns 40,221 shares of the company's stock valued at $143,000 after purchasing an additional 4,125 shares during the period. BNP Paribas Financial Markets lifted its position in Aquestive Therapeutics by 78.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company's stock valued at $31,000 after purchasing an additional 4,134 shares during the period. Finally, The Manufacturers Life Insurance Company lifted its position in Aquestive Therapeutics by 16.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 32,073 shares of the company's stock valued at $106,000 after purchasing an additional 4,557 shares during the period. Institutional investors own 32.45% of the company's stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.